Particle size and cholesterol content of circulating HDL correlate with cardiovascular death in chronic heart failure.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 02 2021
Historique:
received: 29 09 2020
accepted: 25 01 2021
entrez: 5 2 2021
pubmed: 6 2 2021
medline: 16 11 2021
Statut: epublish

Résumé

Evidence regarding any association of HDL-particle (HDL-P) derangements and HDL-cholesterol content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the prognostic value of HDL-P size (HDL-Sz) and the number of cholesterol molecules per HDL-P for CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL-P number, subfractions and HDL-Sz were measured using 1H-NMR spectroscopy. The HDL-C/P ratio was calculated as HDL-cholesterol over HDL-P. Endpoint was CV death, with non-CV death as the competing event. 422 patients were included and followed-up during a median of 4.1 (0-8) years. CV death occurred in 120 (30.5%) patients. Mean HDL-Sz was higher in CV dead as compared with survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage of small HDL-P (54.6% vs. 60% for CV-death vs. alive; p < 0.001). HDL-C/P ratio was higher in the CV-death group (51.0 vs. 48.3, p < 0.001). HDL-Sz and HDL-C/P ratio were significantly associated with CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01-1.47], p = 0.041 and HR 1.04 [95% CI 1.01-1.07], p = 0.008 respectively). HDL-Sz and HDL-C/P ratio are independent predictors of CV death in chronic HF patients.

Identifiants

pubmed: 33542459
doi: 10.1038/s41598-021-82861-6
pii: 10.1038/s41598-021-82861-6
pmc: PMC7862293
doi:

Substances chimiques

Biomarkers 0
Cholesterol, HDL 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3141

Références

J Am Heart Assoc. 2014 Sep 23;3(5):e001221
pubmed: 25249300
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
N Engl J Med. 2007 Nov 22;357(21):2109-22
pubmed: 17984165
Ann Intern Med. 2009 Jan 20;150(2):84-93
pubmed: 19153411
J Proteome Res. 2019 Nov 1;18(11):4038-4045
pubmed: 31503497
Dis Markers. 2008;25(4-5):267-78
pubmed: 19126970
J Am Coll Cardiol. 2018 Feb 13;71(6):620-632
pubmed: 29420958
Circulation. 2013 Sep 10;128(11):1189-97
pubmed: 24002795
Atherosclerosis. 2014 Nov;237(1):163-8
pubmed: 25240111
J Am Soc Echocardiogr. 2004 Oct;17(10):1086-119
pubmed: 15452478
Trends Mol Med. 2011 Oct;17(10):594-603
pubmed: 21839683
Congest Heart Fail. 2007 Nov-Dec;13(6):336-41
pubmed: 18046092
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207961
Sci Rep. 2017 Apr 18;7:46642
pubmed: 28418031
JAMA. 2009 Nov 11;302(18):1993-2000
pubmed: 19903920
J Lipid Res. 2015 Mar;56(3):737-46
pubmed: 25568061
Atherosclerosis. 2007 Nov;195(1):122-8
pubmed: 17011566
Atherosclerosis. 2016 Mar;246:229-35
pubmed: 26803432
N Engl J Med. 2012 Nov 29;367(22):2089-99
pubmed: 23126252
Am J Med. 1977 May;62(5):707-14
pubmed: 193398
J Am Heart Assoc. 2014 Jun 25;3(3):e000902
pubmed: 24965026
Clin Chem. 2017 Jan;63(1):288-296
pubmed: 27811210
N Engl J Med. 2011 Dec 15;365(24):2255-67
pubmed: 22085343
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
J Am Coll Cardiol. 2019 Jan 22;73(2):177-186
pubmed: 30654890
J Am Coll Cardiol. 2003 Dec 3;42(11):1933-40
pubmed: 14662255
Atherosclerosis. 2016 Aug;251:454-459
pubmed: 27320173
Circulation. 2012 May 22;125(20):2469-78
pubmed: 22539783
J Am Coll Cardiol. 2012 Aug 7;60(6):508-16
pubmed: 22796256
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Eur Heart J. 2015 Jan 1;36(1):22-30
pubmed: 24980493
Circulation. 2006 Mar 28;113(12):1556-63
pubmed: 16534013
J Clin Lipidol. 2011 Mar-Apr;5(2):105-13
pubmed: 21392724
Sci Rep. 2016 Jan 18;6:19249
pubmed: 26778677
Clin Chim Acta. 2019 Mar;490:81-87
pubmed: 30578754
J Clin Lipidol. 2013 Sep-Oct;7(5):484-525
pubmed: 24079290
J Am Coll Cardiol. 2015 Feb 3;65(4):355-363
pubmed: 25634834

Auteurs

Albert Teis (A)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain. a_teis@yahoo.es.
Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. a_teis@yahoo.es.

G Cediel (G)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

N Amigó (N)

Biosfer Teslab, SL, Reus, Spain.
Metabolomics Platform, Rovira i Virgili University (URV), Instituto de Investigación Sanitaria Pere Virigili (IISPV), Tarragona, Spain.
Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.

J Julve (J)

Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau i Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain.

J Aranyó (J)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

J Andrés-Cordón (J)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

C Puig-Jové (C)

Endocrinology and Nutrition Department, Germans Trias University Hospital, Badalona, Barcelona, Spain.

E Castelblanco (E)

Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau i Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain.
Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

F Gual-Capllonch (F)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

E Ferrer-Sistach (E)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

N Vallejo (N)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

G Juncà (G)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

J López-Ayerbe (J)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.

M De Antonio (M)

Heart Institute, Heart Failure Unit, Germans Trias University Hospital, Badalona, Barcelona, Spain.

M Domingo (M)

Heart Institute, Heart Failure Unit, Germans Trias University Hospital, Badalona, Barcelona, Spain.

E Santiago-Vacas (E)

Heart Institute, Heart Failure Unit, Germans Trias University Hospital, Badalona, Barcelona, Spain.

P Codina (P)

Heart Institute, Heart Failure Unit, Germans Trias University Hospital, Badalona, Barcelona, Spain.

D Mauricio (D)

Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau i Institut d'Investigació Biomèdica de l'Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain.
Endocrinology and Nutrition Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Lleida Biomedical Research Institute's Dr. Pifarré Foundation (IRBLleida), University of Lleida, Lleida, Spain.

J Lupón (J)

Heart Institute, Heart Failure Unit, Germans Trias University Hospital, Badalona, Barcelona, Spain.

Nuria Alonso (N)

Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. nalonso.germanstrias@gencat.cat.
Center for Biomedical Research on Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain. nalonso.germanstrias@gencat.cat.
Endocrinology and Nutrition Department, Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain. nalonso.germanstrias@gencat.cat.

A Bayes-Genis (A)

Heart Institute, Cardiology Department, Germans Trias University Hospital, Carretera de Canyet s/n, 08916, Badalona, Barcelona, Spain.
Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
Centre for Biomedical Research on cardiovascular Diseases (CIBERCV), Instituto de Salud Carlos III, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH